2026-10-13T16:39:57Z https://api.figshare.com/v2/oai

oai:figshare.com:article/34025665 2026-09-29T17:24:28Z category_7 category_19 category_21 category_873 category_46 category_64 category_132 category_134 portal_5 item_type_1 month_year_09_2026

<p>The progression-free survival (PFS) (A) and overall survival (OS) (B) survival curves comparing the immune checkpoint inhibitors (ICI) plus Anlotinib group with the ICI plus Apatinib group.</p> Lele Chang (15288409) Yaxin Kang (5629136) Mingxuan Zhu (10041395) Jing Liu (38537) Chunyan Lan (18117744) Qin Xu (93193) Medicine Pharmacology Biotechnology Chemical Sciences not elsewhere classified Immunology Cancer Infectious Diseases Virology tyrosine kinase inhibitors tki conventional treatments physician &# 8217 palmoplantar erythrodysesthesia syndrome objective response rate grade &# 8805 common driver mutations 52 %&# 8722 31 &# 8211 26 &# 8211 25 %&# 8722 observed adverse events fujian cancer hospital dcr ), progression 004 ), hypothyroidism immune checkpoint inhibitors related adverse events 001 ), rash 001 ), proteinuria metastatic cervical cancer comparing icis combined cervical cancer adverse reactions 001 ). related deaths os ), 24 ), 010 ), 3 immune xlink "> statistically significant significantly longer retrospective data primary endpoint os difference orr ), free survival 13 months 06 %) 033 ). 03 months <p>The progression-free survival (PFS) (A) and overall survival (OS) (B) survival curves comparing the immune checkpoint inhibitors (ICI) plus Anlotinib group with the ICI plus Apatinib group.</p> 2026-09-29T17:24:25Z Image Figure 10.1371/journal.pone.0350571.s002 https://figshare.com/articles/figure/_p_The_progression-free_survival_PFS_A_and_overall_survival_OS_B_survival_curves_comparing_the_immune_checkpoint_inhibitors_ICI_plus_Anlotinib_group_with_the_ICI_plus_Apatinib_group_p_/34025665 CC BY 4.0